Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
25.88
+0.10 (+0.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
November 02, 2022
EXEL earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
October 29, 2022
With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.
Via
The Motley Fool
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
September 08, 2022
Via
Benzinga
Recap: Exelixis Q2 Earnings
August 09, 2022
Exelixis (NASDAQ:EXEL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
October 28, 2022
Both drugmakers have outperformed the market in the past year.
Via
The Motley Fool
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution
October 19, 2022
These stocks have low-to-no debt, and analysts see tons of upside.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
October 18, 2022
Upgrades
Via
Benzinga
Exelixis Handily Beats Second-Quarter Expectations, Retains 2022 Outlook
August 09, 2022
Exelixis stock was flat immediately after the earnings release.
Via
Investor's Business Daily
Exelixis-BioInvent Establish Immuno-Oncology Pact
June 16, 2022
Via
Benzinga
The Smartest Stocks to Buy With $20 Right Now
October 14, 2022
Cheap stocks have the ability to generate enormous, long-term profits for investors.
Via
The Motley Fool
These 7 Biotech Stocks Are Set to Boom in 2023
October 10, 2022
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023
Via
InvestorPlace
3 Biotech Stocks to Buy Now for Extraordinary Gains
September 20, 2022
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.
Via
InvestorPlace
Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients
September 12, 2022
Via
Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
July 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
June 24, 2022
Upgrades
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
June 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
May 24, 2022
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!
Via
InvestorPlace
This Biotech Looks Good With Increased M&A activity
May 20, 2022
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
May 19, 2022
Via
Benzinga
Exelixis: Q1 Earnings Insights
May 10, 2022
Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
Via
Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
April 21, 2022
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.